Results from the OAC-ALONE trial reported at TCT 2018 and published in Circulation

The first randomized trial of its kind was unable to establish non-inferiority of oral anticoagulation (OAC) alone to combined OAC and a single antiplatelet agent (APT) in patients with atrial fibrillation (AF) and stable coronary artery disease beyond one year after stent implantation.

Go to Source

(Visited 1 times, 1 visits today)

Site Footer

Sliding Sidebar